I can only tell you what is publicly made available by the Company.
In relation to the CHM CDH-17 trial.
In the 'Stocks Down Under' interview conducted on 05/06/24 Rebecca stated that it was 35 days between patients. They have to take it slowly because it's the first time it's been tested in humans.
In the 'Kalkine Media' interview conducted on 29/07/24 Rebecca stated that the first patient was enrolled on that day (or close to it). Go-slow for the first three patients. Aim was to dose 15 patients over a 12-month period. Now it was 28 days between patients and once deemed safe they could go faster.
In October 2024, they dosed their second patient and we were told that 'things are starting to pick up now."
They had dosed their third patient by the end of the year based on the comment in the Quarterly released 31/01/25.
They dosed patient number 4 in the last Quarter.
Patient number 5 had their manufacturing run completed in February as per the 'Proactive Investors' interview on 24/02/25. Still waiting to hear when they will be dosed.
That's all I can assist you with in relation to timing. Let me know what else I can help with.
CHM Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)